FT  15 FEB 92 / Finance &amp; The Family (At a Glance): Wellcome shrugs off
criticism
Wellcome shares were barely dented this week by a Channel 4 programme
critical of its anti-Aids drug, AZT. The stock was one of the best
performers of last year and is now one of the highest rated companies on the
stock market, with a price-earnings ratio in the high 30s.
